Chronic Obstructive Pulmonary Disease (COPD) Research / Adipokines, Inflammation, and Metabolic Diseases · Journal article

Metabolic syndrome in chronic obstructive pulmonary disease: paradoxical relationships between systemic inflammation, oxygenation, and lipid profiles with implications for one-year clinical outcomes

Egyptian Journal of Bronchology · August 13, 2026

Promising Why this matters to you Expert discussion

Encouraging direction, but not yet definitive.

AI Summary

This prospective cohort study of 184 COPD patients found metabolic syndrome in 23.9% of the cohort, associated with significantly higher one-year mortality (p = 0.02) and exacerbation rates (p = 0.001). The study identifies MS as a marker of worse COPD outcomes and reveals inverse correlations between inflammatory markers and lipid levels, but does not establish causality or test interventions.

What was studied

Prospective cohort study. 184 patients with confirmed COPD; enrolled at baseline with follow-up for one year to assess mortality and exacerbation outcomes.. n = 184.

Key findings

Metabolic syndrome prevalence 23.9% in COPD cohort (184 patients) Overall one-year mortality 44.6%; higher in MS group (p = 0.02) One-year exacerbation rate 68.5%; higher in MS group (p = 0.001)

Safety

Confidence intervals not reported for mortality and exacerbation comparisons. Effect sizes (absolute risk differences or odds ratios) for MS-mortality and MS-exacerbation associations not quantified.

Who this may help

Clinicians should consider metabolic screening in COPD patients using NCEP ATP III criteria, as MS presence identifies a higher-risk subgroup for mortality and exacerbations. However, this is an observational association; the study does not evaluate whether MS treatment alters outcomes.

Plain-language summary

Prospective cohort study with moderate sample size (184 patients) showing MS prevalence and one-year mortality/exacerbation associations in COPD, but limited by single-centre design, lack of comparator arm, and reliance on observational follow-up rather than intervention.

Study design

As stated by the source record.

MethodsBaseline demographic, clinical, laboratory data (inflammatory markers, lipid profile, metabolic parameters) collected at enrollment in 184 COPD patients. MS defined by NCEP ATP III criteria (≥3 of: central obesity, elevated triglycerides, reduced HDL-C, elevated BP, elevated fasting glucose or treatment). Patients followed one year to document mortality and exacerbations. Multivariable logistic regression performed to identify independent predictors of mortality and exacerbation.

DesignProspective cohort study

Population184 patients with confirmed COPD; enrolled at baseline with follow-up for one year to assess mortality and exacerbation outcomes.

Sample size184

Reported figures

Quoted from the source exactly as published.

MS prevalence23.9%

Sample size184

Overall one-year mortality44.6%

One-year exacerbation rate68.5%

p-value (MS association with mortality)p = 0.02

p-value (MS association with exacerbations)p = 0.001

Clinical bottom line

Caveats

Single-centre design; geography and setting not stated; generalizability unclear.
No control or comparator arm; observational associations do not establish causality.
Confidence intervals not reported for mortality and exacerbation comparisons.
Effect sizes (absolute risk differences or odds ratios) for MS-mortality and MS-exacerbation associations not quantified.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

moderate

Prospective follow-up cohort with one-year outcomes; no randomization or control arm.

Directness

strong

Directly examines MS prevalence and hard clinical endpoints (mortality, exacerbation) in COPD population.

Consistency

insufficient

No comparison studies cited; single-centre design limits generalizability.

Risk of bias

moderate

Observational design with potential confounding; multivariable analysis attempted but unmeasured confounders possible.

Sample adequacy

moderate

184 total patients analysed with 44.6% mortality event rate; adequate for descriptive analysis but modest for subgroup comparisons.

Source abstract

Abstract Background Chronic obstructive pulmonary disease (COPD) was recognized as a systemic disorder frequently accompanied by metabolic comorbidities, including metabolic syndrome (MS). The coexistence of COPD and MS was thought to amplify systemic inflammation, alter metabolic and lipid profiles, and adversely affect clinical outcomes. However, the prevalence of MS in COPD and its prognostic impact on mortality and exacerbations had not been fully defined. This study aimed to estimate the prevalence of metabolic syndrome among patients with COPD and to examine its association with one-year mortality and exacerbation outcomes, as well as its interplay with systemic inflammation, oxygenation status, and lipid profile parameters. Methods A prospective follow-up study included 184 patients with confirmed COPD. Baseline demographic, clinical, and laboratory data, including inflammatory markers, lipid profile, and metabolic parameters, were collected at enrollment. Metabolic syndrome was defined according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria, requiring at least three of the following: central obesity, elevated triglycerides, reduced HDL cholesterol, elevated blood pressure, or elevated fasting glucose (or corresponding treatment). Patients were followed for one year to document mortality and COPD exacerbations. Multivariable logistic regression analyses were performed to identify predictors of mortality and exacerbation. Results Metabolic syndrome was identified in 23.9% of the COPD cohort. Patients with MS were significantly older and experienced more frequent exacerbations, greater oral corticosteroid use, and higher utilization of home oxygen therapy. During the one-year follow-up period, overall mortality was 44.6%, and 68.5% of patients experienced at least one exacerbation. COPD patients with MS had significantly higher one-year mortality ( p = 0.02) and exacerbation rates ( p = 0.001) compared with those without MS. Increasing age, elevated C-reactive protein, and diabetes mellitus independently predicted mortality, whereas smoking, elevated inflammatory markers, low HDL-C, and lower hemoglobin levels predicted exacerbations. Inverse correlations were observed between inflammatory markers and total cholesterol and LDL, while oxygen saturation was positively associated with lipid levels. Triglyceride levels were positively correlated with HbA1c. Conclusion Metabolic syndrome was common among patients with COPD and was associated with worse clinical outcomes, including increased mortality and exacerbations. The observed paradoxical relationships between inflammation, oxygenation, and lipid profiles highlighted the complex systemic nature of COPD and underscored the importance of comprehensive metabolic and inflammatory assessment to improve risk stratification and management.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Eman M. MoazenAsmaa AliAmr Aly ElshormilisyChronic Obstructive Pulmonary Disease (COPD) ResearchDalia Anas IbrahimLiang WuAdipokines, Inflammation, and Metabolic DiseasesSeham Ezzat Fathy Elfeky